Drug Type Small molecule drug |
Synonyms- |
Target |
Action antagonists |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H27F4N7O2 |
InChIKeyBFSRTTWIPACGMI-UHFFFAOYSA-N |
CAS Registry1375465-09-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
EGFR Mutation Lung Cancer | Phase 1 | United States | 15 Apr 2013 | |
EGFR Mutation Lung Cancer | Phase 1 | United States | 15 Apr 2013 | |
EGFR Mutation Lung Cancer | Phase 1 | United Kingdom | 15 Apr 2013 |